Ixekizumab (an anti-IL-17A monoclonal antibody) is superior to placebo for the treatment of DMARD-naive patients with ankylosing spondylitis (AS), according to the 16-week results of the COAST-V phase III randomized controlled trial (341 patients, randomized 1:1:1:1). More patients achieved the stringent Assessment of Spondyloarthritis International Society 40% response primary endpoint when treated with ixekizumab (every 2 weeks = 52%; every 4 weeks = 48%) than with placebo (every 2 weeks = 18%), results that were not inferior to treatment with a TNF inhibitor (every 2 weeks = 36%).
References
Original article
van der Heijde, D. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet https://doi.org/10.1016/S0140-6736(18)31946-9 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. IL-17A blockade effective for AS. Nat Rev Rheumatol 14, 684 (2018). https://doi.org/10.1038/s41584-018-0117-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0117-2
This article is cited by
-
Maternal Mid-Gestation Cytokine Dysregulation in Mothers of Children with Autism Spectrum Disorder
Journal of Autism and Developmental Disorders (2022)
